Alternative Model to Transform a Funding Gap in Rare Disease Clinical Research

Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised by a wealthy individual primarily, in return for being in the trial. At DPharm Europe, Pfizer's Craig Lipset interviewed on stage Alexander to share his story. We are delighted to present the journey and latest updates on PharmaTalk Radio. 

• The story of the formation of iCancer.org.uk and the Oncolytic Virus Fund
• An alternative way to make clinical trials more accessible
• Ethical and moral issues
• A possible disruptive and sustainable model for other neglected medicines

The next DPharm: Disruptive Innovations to Advance Clinical Trials event takes place September 20-21 in Boston. DPharm Europe is scheduled for February 8-9, 2017 in London. For more information about these events or our Immuno-Oncology events, visit, www.theconferenceforum.org.

Producer:

Valerie Bowling
Executive Director, Conference Forum & Pharma Talk Radio

Guest Host:

Craig Lipset, MBA
Head of Clinical Innovation, R&D, Pfizer

Guest:

Alexander Masters
Author, Medical Campaigner and Co-Founder, iCancer.org.uk